New Hampshire Code of Administrative Rules
Den - State Board of Registration of Funeral Directors and Embalmers
Chapter Den 500 - ETHICAL AND PROFESSIONAL DUTIES
Part Den 502 - PROFESSIONAL DUTIES
Section Den 502.01 - Professional Misconduct
Universal Citation: NH Admin Rules Den 502.01
Current through Register No. 40, October 3, 2024
(a) Dentists shall, pursuant to RSA 317-A:17, II (j), be under a professional duty to comply with the requirements of the Controlled Drug Prescription Health and Safety Program (PDMP), RSA 318-A:31-38, and all administrative rules of the board of pharmacy adopted thereunder.
(b) Pursuant to RSA 318-B:36, the following actions shall result in a disciplinary proceeding and the imposition of sanctions by the board in accordance with its rules:
(1) Prescribing or
dispensing of controlled substances in schedules II-IV after June 30, 2015
without having registered with the program;
(2) The knowing disclosure of program
information by a person authorized to receive it in a manner that violates RSA
318-B or administrative rules of the board of pharmacy;
(3) The use of program information by a
person authorized to receive it for a purpose that violates RSA 318-B or
administrative rules of the board of pharmacy; and
(4) Permitting the use or disclosure of
program information under control of the dentist by a person not authorized to
receive it in violation of RSA 318-B or administrative rules of the board of
pharmacy.
(c) When prescribing any controlled substance for use in pain control, licensees shall:
(1) Document prescription for such controlled
substances, and when prescribing an opioid for acute pain, provide the patient
with information that contains the following:
a. Risk of side effects, including addiction
and overdose resulting in death;
b.
Risks of keeping unused medication;
c. Options for safely disposing of unused
medication; and
d. Danger in
operating motor vehicle or heavy machinery;
(2) Utilize appropriate treatment standards
for the treatment of chronic pain, including:
a. Utilization of an informed consent that
explains the following risks associated with opioids:
1. Addiction;
2. Overdose and death;
3. Physical dependence;
4. Physical side effects;
5. Tolerance; and
6. Crime victimization; and
b. Proper patient evaluation,
including a risk assessment. A risk assessment means a process for predicting a
patient's likelihood of misusing or abusing opioids in order to develop and
document a level of monitoring for that patient. An example of a screening tool
is the Screener and Opioid Assessment for Patients with Pain (SOAPP), but
prescribers can use any evidence-based screening tool.
c. Creation of a treatment plan;
d. A written pain agreement;
e. Appropriate consultations;
f. Periodic review and follow-up;
and
g. Appropriate toxicology
screening;
(3) Comply
with all federal and state controlled substances laws, rules, and
regulations;
(4) Adhere to the
principles outlined in the Federation of State Medical Boards Model Policy on
the Use of Opioid Analgesics in the Treatment of Chronic Pain, July
2013;
(5) Adhere to the principles
outlined in the Clinical Guidelines for the Use of Buprenorphine in the
Treatment of Opioid Addiction, A Treatment Improvement Protocol by the U.S.
Department of Health and Human Services (2004) found at
http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf ;
and
(6) Adhere to the principles
outlined in the New Hampshire Dental Society "Opioids in the Dental Practice
Guidelines for New Hampshire Dentists".
The amended version of this section by New Hampshire Register Volume 36, Number 28, eff.6/29/2016 is not yet available.
Disclaimer: These regulations may not be the most recent version. New Hampshire may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
